Retrophin intends to price $40 million public offering of common stock

Deal funds clinical trials and development, general corporate purposes

By Devika Patel

Knoxville, Tenn., Jan. 7 - Retrophin, Inc. said it will raise $40 million in its public sale of common stock. The deal was announced on Dec. 18 and was incorrectly identified as an initial public offering.

Jefferies LLC is the bookrunning manager. Roth Capital Partners, Ladenburg Thalmann & Co. Inc. and Summer Street Research Partners are the co-managers.

Proceeds will be used to obtain regulatory approval for the reintroduction of Syntocinon into the U.S. market, for clinical trials, to advance the company's early stage development programs, for product development and general corporate purposes.

The biopharmaceutical company is based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.